#hyperphosphataemia
LightNews LightNews
thelancetendo.bsky.social
Emerging diagnostic technologies, including targeted genetic testing, #parathyroid autoimmunity assays, and point-of-care calcium monitoring, could enable individualised & real-time management of #hypoparathyroidism thelancet.com/journals/lan...
#PTH #hypocalcaemia #hyperphosphataemia

#EndoSky
October 4, 2026 at 8:55 AM
thelancetendo.bsky.social
Despite advances in #hypoparathyroidism management, important unmet needs remain, including earlier identification of genetic forms and improved therapies to reduce complications and optimise quality of life (QoL) www.thelancet.com/journals/lan...
#hypocalcaemia #hyperphosphataemia #PTH

#EndoSky
Hypoparathyroidism: translating science from the laboratory to the clinic
Chronic hypoparathyroidism is a rare endocrine disorder characterised by hypocalcaemia due to insufficient parathyroid hormone (PTH) that is associated with a multidimensional reduced quality of life,...
www.thelancet.com
September 19, 2026 at 12:59 PM
theoncologynetwork.bsky.social
🎧 NEW PODCAST | How do you manage the unique toxicities associated with FGFR inhibitors in #iCCA? Join A/Prof Jenny Liu + Prof John Bridgewater as they discuss:

✔️ Early molecular testing
✔️ Hyperphosphataemia & mucositis
✔️ Nail, skin & eye toxicities
✔️ And much more...

Listen now: t.ly/kjU3b
July 29, 2026 at 10:15 PM
thelancetendo.bsky.social
Chronic hypoparathyroidism is a rare endocrinopathy characterised by hypocalcaemia and hyperphosphataemia due to the absence or severe deficiency of parathyroid hormone (PTH) www.thelancet.com/journals/lan...
#hypoparathyroidism #parathyroid

#MedSky #EndoSky
Hypoparathyroidism: translating science from the laboratory to the clinic
Chronic hypoparathyroidism is a rare endocrine disorder characterised by hypocalcaemia due to insufficient parathyroid hormone (PTH) that is associated with a multidimensional reduced quality of life,...
www.thelancet.com
September 9, 2026 at 6:50 AM
pharmaphorum.bsky.social
#UnicyciveTherapeutics' hopes of getting #FDA approval of its drug for #hyperphosphataemia in patients with #chronickidneydisease (CKD) who need #dialysis have been knocked back again.
Unicycive hits another hurdle with hyperphosphataemia drug
Unicycive Therapeutics' hopes of getting FDA approval of its drug for hyperphosphataemia in dialysis patients have been knocked back again.
buff.ly
June 30, 2026 at 2:15 PM
kinetoplastpapers.bsky.social
Hyperphosphataemia and NADPH Oxidase Regulation in Pathophysiological Processes: Implications for Oxidative Stress and Disease Progression pubmed.ncbi.nlm.nih.gov/40298783/
April 30, 2025 at 10:57 PM